I was intrigued by a headline I read announcing that Saxo had implemented a new drug-monitoring programme. Does this, I asked its joint chief executive Lars Seier Christensen, mean that it will now be able to get rid of anyone who screws up its P&L more easily? But I was too prompt in my assumption: the testing policy concerns the professional cycling team that the bank sponsors. Still, mustn’t let the facts get in the way of a good story.